UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 686

Sortiert nach

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

Diabetic medicine, 2014-02, Vol.31 (2), p.176-184

2014

Volltextzugriff (PDF)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.386-394

2015

Volltextzugriff (PDF)

Diabetes and breast cancer risk: a meta-analysis

Breast cancer research and treatment, 2012-10, Vol.107 (9), p.1608-1617

2012

Volltextzugriff (PDF)

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

Diabetes & metabolism, 2013-12, Vol.39 (6), p.485-496

2013

Volltextzugriff (PDF)

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.859-867

2015

Volltextzugriff (PDF)

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial

Diabetic medicine, 2006-02, Vol.23 (2), p.141-147

2006

Volltextzugriff (PDF)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.366-374

2016

Volltextzugriff (PDF)

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2014-07, Vol.16 (7), p.588-601

2014

Volltextzugriff (PDF)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.375-383

2016

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1142-1149

2015

Volltextzugriff (PDF)

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.835-842

2015

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)

Diabetes & metabolism, 2017-10, Vol.43 (5), p.446-452

2017

Volltextzugriff (PDF)

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

Diabetes, obesity & metabolism, 2008, Vol.10 (1), p.82-90

2008

Volltextzugriff (PDF)

Insulins today and beyond

The Lancet (British edition), 2001-09, Vol.358 (9283), p.739-746

2001

Volltextzugriff (PDF)

Alternative routes of insulin delivery

Diabetic medicine, 2003-11, Vol.20 (11), p.886-898

2003

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

Diabetes & metabolism, 2020-04, Vol.46 (2), p.110-118

2020

Volltextzugriff (PDF)

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials

Diabetes & metabolism, 2015-12, Vol.41 (6), p.6S16-6S20

2015

Volltextzugriff (PDF)

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Diabetes & metabolism, 2019-09, Vol.45 (4), p.330-340

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro

Diabetes (New York, N.Y.), 2000-12, Vol.49 (12), p.2142-2148

2000

Volltextzugriff (PDF)

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

Diabetic medicine, 2004-11, Vol.21 (11), p.1213-1220

2004

Volltextzugriff (PDF)

Insulin analogues and their potential in the management of diabetes mellitus

Diabetologia, 1999-10, Vol.42 (10), p.1151-1167

1999

Volltextzugriff (PDF)

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Diabetes & metabolism, 2016-04, Vol.42 (2), p.77-79

2016

Volltextzugriff (PDF)

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population

Nutrition, metabolism, and cardiovascular diseases, 2019-05, Vol.29 (5), p.496-503

2019

Volltextzugriff (PDF)

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.589-595

2009

Volltextzugriff (PDF)

Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes

Diabetes & metabolism, 2018-09, Vol.44 (4), p.368-372

2018

Volltextzugriff (PDF)

1 – 25 von 686

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(572)
Mit Volltextzugriff
(538)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(413)
Humans
(372)
Life Sciences & Biomedicine
(371)
Male
(226)
Female
(212)
Biological And Medical Sciences
(205)
Adult
(191)
Medical Sciences
(183)
Endocrinology & Metabolism
(159)
Middle Aged
(143)
Cardiovascular System & Cardiology
(112)
Cardiac & Cardiovascular Systems
(101)
Blood Glucose - Metabolism
(96)
Endocrinopathies
(74)
Insulin
(74)
Animals
(69)
Endocrine Pancreas. Apud Cells
(69)
Insulin - Blood
(69)
Aged
(67)
Diabetes
(64)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

Diabetes and breast cancer risk: a meta-analysis

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

Insulins today and beyond

Alternative routes of insulin delivery

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

Insulin analogues and their potential in the management of diabetes mellitus

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes

Suchergebnisse filtern